CN108107218B - 抗体测定 - Google Patents

抗体测定 Download PDF

Info

Publication number
CN108107218B
CN108107218B CN201711213227.4A CN201711213227A CN108107218B CN 108107218 B CN108107218 B CN 108107218B CN 201711213227 A CN201711213227 A CN 201711213227A CN 108107218 B CN108107218 B CN 108107218B
Authority
CN
China
Prior art keywords
tumor marker
antigen
mmp9
epcam
aif1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711213227.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108107218A (zh
Inventor
贾里德·艾伦
伊莎贝尔·麦克唐纳
安德烈亚·默里
克里斯托弗·韦尔拜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furim Co ltd
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Priority to CN202110715736.7A priority Critical patent/CN113655224A/zh
Publication of CN108107218A publication Critical patent/CN108107218A/zh
Application granted granted Critical
Publication of CN108107218B publication Critical patent/CN108107218B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201711213227.4A 2016-11-25 2017-11-27 抗体测定 Active CN108107218B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110715736.7A CN113655224A (zh) 2016-11-25 2017-11-27 抗体测定

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1619954.9 2016-11-25
GBGB1619954.9A GB201619954D0 (en) 2016-11-25 2016-11-25 Antibody assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110715736.7A Division CN113655224A (zh) 2016-11-25 2017-11-27 抗体测定

Publications (2)

Publication Number Publication Date
CN108107218A CN108107218A (zh) 2018-06-01
CN108107218B true CN108107218B (zh) 2021-10-08

Family

ID=58073509

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711213227.4A Active CN108107218B (zh) 2016-11-25 2017-11-27 抗体测定
CN202110715736.7A Pending CN113655224A (zh) 2016-11-25 2017-11-27 抗体测定

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110715736.7A Pending CN113655224A (zh) 2016-11-25 2017-11-27 抗体测定

Country Status (13)

Country Link
US (1) US20190376975A1 (https=)
EP (1) EP3545309B1 (https=)
JP (1) JP7249284B2 (https=)
KR (1) KR20190088510A (https=)
CN (2) CN108107218B (https=)
AU (1) AU2017365931A1 (https=)
BR (1) BR112019010636A2 (https=)
CA (1) CA3044492A1 (https=)
GB (1) GB201619954D0 (https=)
IL (1) IL266857A (https=)
MX (1) MX2019006098A (https=)
RU (1) RU2769987C2 (https=)
WO (1) WO2018096351A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109116023B (zh) * 2018-06-14 2021-06-04 郑州大学第一附属医院 一种肺癌标志物抗-mmp12自身抗体及其应用
CN109709335B (zh) * 2018-12-18 2020-10-27 中国医学科学院基础医学研究所 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用
CN109633165B (zh) * 2018-12-18 2021-03-09 中国医学科学院基础医学研究所 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用
ES3039706T3 (en) * 2019-02-19 2025-10-24 Otsuka Denshi Kk Method for determining condition parameters for photodynamic therapy and photodynamic therapy apparatus
CN110579611B (zh) * 2019-09-18 2023-01-31 郑州大学 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法
JPWO2022118947A1 (https=) * 2020-12-04 2022-06-09
CN114994318A (zh) * 2022-06-16 2022-09-02 深圳上泰生物工程有限公司 一种用于检测akr1b10的试剂盒及其制备方法
CN116444680B (zh) * 2022-12-28 2024-05-03 杭州凯保罗生物科技有限公司 一种ralgds-krt8-aif1融合肿瘤抗原蛋白的制备方法及其应用
CN119639903B (zh) * 2025-01-17 2025-11-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于肝内胆管癌的生物标记物、药物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065541A2 (en) * 2008-12-02 2010-06-10 Tzu-Ling Tseng Biomarkers useful in liver fibrosis diagnosis
WO2011099435A1 (ja) * 2010-02-12 2011-08-18 日東紡績株式会社 Ｋｕ８６とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
CN102175864A (zh) * 2011-01-19 2011-09-07 江苏永鼎股份有限公司 一组早期肝癌分子标志物及其应用
JP2014240771A (ja) * 2013-06-11 2014-12-25 日東紡績株式会社 Ｋｕ７０／Ｋｕ８６ヘテロダイマーに対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
ITPD20030264A1 (it) * 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
TWI281473B (en) * 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
CN1632589A (zh) * 2003-12-24 2005-06-29 财团法人工业技术研究院 肝脏疾病的生物标记分子及其检测方法
US20080254481A1 (en) * 2006-11-13 2008-10-16 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
CN102356316B (zh) * 2009-03-05 2015-07-08 独立行政法人产业技术综合研究所 肝内胆管癌的检出、辨别方法
CN102507938B (zh) * 2011-10-08 2014-12-24 复旦大学附属中山医院 一种肝癌转移预测定量抗体芯片及试剂盒
US20150185226A1 (en) * 2012-07-23 2015-07-02 Inserm (Institut National De La Sante Et La Recherche Medicale) Method for Diagnosing Scleroderma
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
GB201411060D0 (en) * 2014-06-20 2014-08-06 Oncimmune Ltd Improved immunoassay method
TWI700493B (zh) * 2014-07-02 2020-08-01 香港商龍勝發展有限公司 用於非侵入性肝癌診斷之特異性生物標記組
CN104990905B (zh) * 2015-06-30 2017-12-29 曲凯 一种基于固相酶联免疫荧光斑点的肝癌转移诊断试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065541A2 (en) * 2008-12-02 2010-06-10 Tzu-Ling Tseng Biomarkers useful in liver fibrosis diagnosis
WO2011099435A1 (ja) * 2010-02-12 2011-08-18 日東紡績株式会社 Ｋｕ８６とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
CN102175864A (zh) * 2011-01-19 2011-09-07 江苏永鼎股份有限公司 一组早期肝癌分子标志物及其应用
JP2014240771A (ja) * 2013-06-11 2014-12-25 日東紡績株式会社 Ｋｕ７０／Ｋｕ８６ヘテロダイマーに対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法

Also Published As

Publication number Publication date
JP7249284B2 (ja) 2023-03-30
WO2018096351A1 (en) 2018-05-31
CN108107218A (zh) 2018-06-01
JP2020515826A (ja) 2020-05-28
RU2019118625A3 (https=) 2021-03-31
CA3044492A1 (en) 2018-05-31
EP3545309A1 (en) 2019-10-02
AU2017365931A1 (en) 2019-06-06
RU2019118625A (ru) 2020-12-25
GB201619954D0 (en) 2017-01-11
US20190376975A1 (en) 2019-12-12
KR20190088510A (ko) 2019-07-26
IL266857A (en) 2019-07-31
MX2019006098A (es) 2019-12-02
RU2769987C2 (ru) 2022-04-12
EP3545309B1 (en) 2021-03-31
CN113655224A (zh) 2021-11-16
BR112019010636A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
CN108107218B (zh) 抗体测定
CN111337678B (zh) 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN106662586B (zh) 改进的免疫测定方法
US20120100558A1 (en) Lung cancer diagnosis
WO2022083673A1 (zh) 食管癌的生物标志物及其应用
WO2022063156A1 (zh) 乳腺癌的生物标志物及其应用
CN115877006B (zh) 卵巢癌相关的生物标志物及其应用
CN109116023B (zh) 一种肺癌标志物抗-mmp12自身抗体及其应用
NO20161585A1 (no) Forbedrede immunoassay metoder
JP7744641B2 (ja) 肺癌における自己抗体を検出するための抗原の組合せの使用
CN116413430B (zh) 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒
CA2799359C (en) Method for the diagnosis/prognosis of colorectal cancer
TW201928351A (zh) 抗體測定
US20230375550A1 (en) Method for diagnosing breast cancer by using biomarker
CN113933509A (zh) 抗体测定
GB2600701A (en) Antibody assay
US20150018239A1 (en) Biomarker set for identifying a severe form of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: British Nottinghamshire

Patentee after: Furim Co.,Ltd.

Country or region after: United Kingdom

Address before: British Nottinghamshire

Patentee before: ONCIMMUNE Ltd.

Country or region before: United Kingdom

CP03 Change of name, title or address